Additional Cancer Therapy Programs

The TVAX® approach to immunotherapy is applicable to numerous cancer types and the company is building a broad oncology product pipeline.  While brain cancer represents the company’s most advanced candidate and clinical program, TVAX also has proof of concept preclinical and human data in breast, colon, lung, melanoma and ovarian cancer.  Published literature studies have proven the applicability of the technology to leukemia, as well as pancreatic and prostate cancer. 

Because of this progress, the company has the potential to develop and advance specific programs for a broad range of other oncology indications.  Safety and toxicity studies have been completed for the TVAX platform, allowing the company to move directly into Phase 2 studies for any additional cancer indications

Scroll to Top